Calling complement component 5 (C5) "on its own an industry [that will] ultimately rival tumor necrosis factor-alpha inhibitors" in regard to the target's usefulness, Ra Pharmaceuticals Inc. CEO Douglas Treco told BioWorld that his firm leads the pack in the field. "Ultimately, we think we can own C5, from a mechanistic point of view," he said.